Floatz Rating
B60/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07389356CT.gov Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06921044CT.gov A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06760039CT.gov Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | — | Recruiting | — | — | — |
NCT06594640CT.gov R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT06244368CT.gov GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | — | Recruiting | — | — | — |
NCT05990985CT.gov The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | — | Not Yet Recruiting | — | — | — |
NCT05875428CT.gov Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | — | Unknown | — | — | — |
NCT05784987CT.gov R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT05777369CT.gov R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT05575973CT.gov Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | — | Unknown | — | — | — |
Show 7 more trialsShow fewer
NCT05823701CT.gov Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | — | Unknown | — | — | — |
NCT02733380CT.gov Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | — | Unknown | — | — | — |
NCT01842672CT.gov Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia | — | Completed | — | — | — |
NCT01144403CT.gov A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | — | Terminated | — | — | — |
NCT00499018CT.gov Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | — | Unknown | — | — | — |
NCT00842595CT.gov Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | — | Completed | — | — | — |
NCT00556127CT.gov Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mitoxantrone (this asset) | The First Affiliated Hospital with Nanjing Medical University | P3 | B · 60 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Mitoxantrone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | BBB · 77 |
| Acute Monocytic Leukemia | — | P2/3 | BBB · 74 |
| Myeloid Neoplasm | — | P3 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mitoxantrone in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mitoxantrone-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →